Key Drivers
- Strong Liquidity
- Minimal Leverage
- Heavy Cash Burn
AIAI Summary
CLDX has shifted from a survival story to a clinical-validation story, with repeated human data and a strong cash runway de-risking near-term financing, but the stock still hinges on whether barzolvolimab and CDX-622 can prove durable late-stage efficacy and avoid dilution as losses continue.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Minimal Leverage
- •Heavy Cash Burn
CLDX has a strong cash-rich balance sheet and minimal debt, but near-zero revenue, persistent operating losses, and heavy cash burn keep earnings quality weak and make future clinical progress the main value driver.
Price Behavior
Key Price Behavior Insights:
- •Breakout hold
- •Higher-high trend
- •Stretched rally
CLDX has trended strongly higher over the last month from $29.77 to $38.37, holding above the broken $31-$34 zone and favoring momentum as long as mid-$30s support holds, though the sharp run leaves it vulnerable to near-term profit-taking.
Fast rise with brief pullbacks, signaling volatility and short-term profit-taking risk
Sentiment & News
Key News Insights:
- •Durable efficacy
- •Strong tolerability
- •Pipeline momentum
Celldex reported encouraging June 2026 clinical updates across barzolvolimab and CDX-622, with durable efficacy signals, good tolerability, and continued support for its mast cell-targeting strategy.
The results reinforce Celldex's clinical execution and may improve investor confidence in the long-term potential of its allergy-focused pipeline
Similar Companies in Healthcare
Other companies in the same sector with AI ratings